Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• A proxy contest is underway for the 2026 annual meeting, with a dissident stockholder, DOMA Perpetual Capital Management LLC, proposing an alternative slate of directors.

• The board urges shareholders to support its nominees and proposals to continue executing the 5x30 long-term value creation strategy.

• Forward-looking statements highlight growth strategies, product development, and market expansion, with caution regarding risks and uncertainties.

Voting matters and shareholder proposals

• Shareholders will vote on the election of three Class III directors: Christopher Christie, Samit Hirawat, and Thomas Wiggans, recommended by the board.

• The board recommends voting FOR the appointment of KPMG as independent auditor, executive compensation, the amended stock plan, and the amended employee stock purchase plan.

• Shareholders are urged to disregard proxy materials from DOMA and withhold votes for DOMA's nominees.

Board of directors and corporate governance

• The board and executive leadership emphasize their commitment to acting in the best interests of all stockholders and maintaining company momentum.

• Information on director nominees and their interests is available in the proxy statement and related SEC filings.